EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Diagnosis of Cardiac Amyloidosis on Echocardiography Using Artificial Intelligence

Adam Ioannou, Michel G. Khouri, Takeshi Kitai, Sreekanth Vemulapalli, Chung-Lieh Hung, Sze Chi Lim, Matthew Frost, Weile Wayne Tee, Josephine Mansell, Awais Sheikh, Lucia Venneri, Yousuf Razvi, Aldostefano Porcari, Ana Martinez-Naharro, Muhammad U. Rauf, Helen Lachmann, Philip N. Hawkins, Ashutosh Wechelakar, William Moody, Francesco Bandera, Justin A. Ezekowitz, Carolyn S.P. Lam, Scott D. Solomon, Julian D. Gillmore, Marianna Fontana

Circulation: Cardiovascular Imaging · 2026-04 · 19 (4)

DOI: 10.1161/circimaging.125.018991 ↗
AbstractBibliografische Angaben

Abstract

BACKGROUND: Diagnosing cardiac amyloidosis (CA) on echocardiography can be challenging due to the imaging overlap between CA and more prevalent causes of a hypertrophic phenotype. This study sought to (1) evaluate the performance of artificial-intelligence (AI) derived measurements incorporated into the established multiparametric echocardiographic scoring system to detect CA; (2) develop and validate an AI-based deep-learning model for video-based detection of CA on echocardiography. METHODS: The study population comprised 5776 patients (CA, 2756; controls, 3020). The training data set included patients from the UK National Amyloidosis Center and Taiwan MacKay Memorial Hospital (CA, 2241; controls, 2130). External test data sets were obtained from the US Duke University Health System (CA, 334; left ventricular hypertrophy controls, 668) and Japan National Cerebral and Cardiovascular Center (CA, 181; left ventricular hypertrophy controls, 222). RESULTS: The multiparametric echocardiographic score computed using AI-derived measurements achieved an accuracy of 79.5% (sensitivity, 75.4%; specificity, 81.5%) in the United States cohort and 79.7% (sensitivity, 81.6%; specificity, 78.1%) in the Japan cohort. The deep-learning model demonstrated accuracies of 96.2% (sensitivity, 96.8%; specificity, 95.7%) and 95.8% (sensitivity, 97.3%; specificity, 94.3%) in the internal validation and internal test sets, respectively. External validation of the deep-learning model showed accuracies of 87.5% (sensitivity, 86.6%; specificity, 87.9%) in the United States and 88.4% (sensitivity, 92.3%; specificity, 85.3%) in the Japanese cohort. Subgroup analysis demonstrated that the deep-learning model showed robust discrimination of CA from other hypertrophic phenocopies: CA versus hypertension (area under the curve [AUC], 0.92 [95% CI, 0.91–0.94]), CA versus hypertrophic cardiomyopathy (AUC, 0.91 [95% CI, 0.87–0.94]), CA versus aortic stenosis (AUC, 0.93 [95% CI, 0.90–0.95]), CA versus chronic kidney disease (AUC, 0.93 [95% CI, 0.91–0.95]). The deep-learning model was able to classify a greater proportion of patients compared with the AI-derived multiparametric echocardiographic score and achieved superior diagnostic accuracy (AUC, 0.93 [95% CI, 0.91–0.95] versus AUC, 0.88 [95% CI, 0.85–0.90]; P

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →